Jay Geoghagan, MD
Cardiovascular Disease · North Little Rock, ARNPI 1407840101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 412 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations.
Across 412 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$790
- Pfizer$719
- Boehringer Ingelheim$581
- E.r. Squibb & Sons, L.L.C.$542
- Amgen$297
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,12699%
- Education$341%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 92 | $1,420 |
| Johnson & Johnson | 62 | $790 |
| Pfizer | 56 | $719 |
| Boehringer Ingelheim | 36 | $581 |
| E.r. Squibb & Sons, L.L.C. | 38 | $542 |
| Amgen | 19 | $297 |
| Novo Nordisk | 13 | $240 |
| AstraZeneca | 16 | $221 |
| Alnylam Pharmaceuticals Inc. | 10 | $183 |
| Merck | 10 | $169 |
| Sanofi-aventis U.S. LLC | 10 | $157 |
| Abbott | 7 | $138 |
| Bayer | 6 | $93 |
| Abiomed | 5 | $82 |
| Lexicon Pharmaceuticals, Inc. | 4 | $70 |
| Amarin Pharma, Inc. | 5 | $64 |
| Philips North America LLC | 2 | $60 |
| Baxter Healthcare | 2 | $51 |
| Actelion Pharmaceuticals US, Inc. | 3 | $46 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $43 |
| Lundbeck LLC | 2 | $32 |
| Braemar Manufacturing, LLC | 1 | $32 |
| Astellas Pharma US Inc | 2 | $29 |
| Bardy Diagnostics, Inc. | 2 | $23 |
| Bridgebio Pharma, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
How this compares
$6,159 in reported general payments places this provider in the 65th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 468 | $379,464 |
| EntrestoSacubitril/Valsartan | 129 | $104,891 |
| XareltoRivaroxaban | 96 | $101,151 |
| JardianceEmpagliflozin | 69 | $54,242 |
| MultaqDronedarone Hcl | 15 | $18,048 |
| BrilintaTicagrelor | 20 | $10,578 |
| Atorvastatin Calcium | 596 | $6,632 |
| Praluent PenAlirocumab | 13 | $6,270 |
| Metoprolol Succinate | 417 | $4,702 |
| Propafenone Hcl ErPropafenone Hcl | 20 | $4,579 |
| Valsartan | 130 | $2,895 |
| Metoprolol Tartrate | 230 | $1,528 |
| Ranolazine ErRanolazine | 31 | $1,405 |
| Bumetanide | 15 | $1,398 |
| Amlodipine Besylate | 276 | $1,351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $719 | $379,464468 claims |
| NovartisEntresto | $1,420 | $104,891129 claims |
| Johnson & JohnsonXarelto | $790 | $101,15196 claims |
| Boehringer IngelheimJardiance | $581 | $54,24269 claims |
| Sanofi-aventis U.S. LLCMultaq | $157 | $18,04815 claims |
| AstraZenecaBrilinta | $221 | $10,57820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in North Little Rock
- Thomas ConleyNorth Little Rock$12K
- Mark St PierreNorth Little Rock$10K
- Morris KelleyNorth Little Rock$10K
- Marvin AshfordNorth Little Rock$7K
- Charles CaldwellNorth Little Rock$5K
- James ParkhurstNorth Little Rock$4K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.